Last update 08 May 2025

Measles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai)

Overview

Basic Info

Drug Type
Combination vaccine, Live attenuated vaccine, Prophylactic vaccine
Synonyms-
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Infectious DiseasesMouth and Tooth DiseasesOther Diseases
Active Indication
MeaslesMumpsRubella
Inactive Indication-
Originator Organization
Beijing Minhai Biological Technology Co., Ltd.Beijing Minhai Biological Technology Co., Ltd.
Active Organization
Beijing Minhai Biological Technology Co., Ltd.Beijing Minhai Biological Technology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Measles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai)
CTR20243777
/ RecruitingPhase 1
本研究为随机、盲态、阳性对照临床试验，用于评价麻腮风联合减毒活疫苗在8月龄及以上健康人群中免疫的安全性和初步免疫原性。
[Translation] This study is a randomized, blinded, positive-controlled clinical trial used to evaluate the safety and preliminary immunogenicity of measles, mumps and rubella combined live attenuated vaccine in healthy people aged 8 months and above.
100 Clinical Results associated with Measles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai)
Login to view more data
100 Translational Medicine associated with Measles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai)
Login to view more data
100 Patents (Medical) associated with Measles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai)
Login to view more data
100 Deals associated with Measles, mumps and rubella combined vaccine, live attenuated (Beijing Minhai)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MeaslesPhase 1
China
Beijing Minhai Biological Technology Co., Ltd.Beijing Minhai Biological Technology Co., Ltd.
20 Nov 2024
MumpsPhase 1
China
Beijing Minhai Biological Technology Co., Ltd.Beijing Minhai Biological Technology Co., Ltd.
20 Nov 2024
RubellaPhase 1
China
Beijing Minhai Biological Technology Co., Ltd.Beijing Minhai Biological Technology Co., Ltd.
20 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free